Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06640725
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-27
Brief Title:
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the HN
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase II Study of TPEx Taxotere-platinum-cetuximab Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck TATIANA
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TATIANA
Brief Summary:
The main objective of this research is to increase the life expectancy of patients with advanced mouth and throat cancer by adding avelumab to the standard TPEx treatment
All participants in this research will receive the same treatment which will take place in two phases
1st phase chemotherapy immunotherapy standard reference treatment Docetaxel cisplatin or carboplatin cetuximab
2nd phase immunotherapy cetuximab combined with avelumab which is the treatment under study
All participants in this research will receive the same treatment which will take place in two phases
1st phase chemotherapy immunotherapy standard reference treatment Docetaxel cisplatin or carboplatin cetuximab
2nd phase immunotherapy cetuximab combined with avelumab which is the treatment under study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None